Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
AMB-220-E is an international, multicenter, open-label study examining the long-term safety
of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study
NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging,
Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to
Severe Pulmonary Arterial Hypertension".